Citations

Clear

2236 citation(s) found for "Ju, Angela".

Hypercontractile phenotype at rest in chronic coronary syndromes predicts impaired functional reserve and increased mortality
Ciampi, Q C Quirino, Cortigiani, Lauro , Zagatina, Angela, Padang, Ratnasari , Kane, Garvan C, Villarraga, Hector R, Arruda‐Olson, Adelaide M. , Kalinina, Elena, Lowenstein, Jorge, Haber, Diego M Lowenstein, Marconi, Sofia, Boshchenko, Alla, Rodriguez-Zanella, Hugo, Wierzbowska-Drabik, Karina, Kasprzak, J D, Merli, Elisa , Djordjevic-Dikic, Ana, Amor, Miguel, Saad, Ariel, Safarova, Ayten, Timofeeva, T. N. , Vazquez, J P, Rigo, Fausto, Nikolic, Aleksandra, Ostojic, M, Kovacevic-Preradovic, Tamara, Cerracchio, Emma, Tripepi, Giovanni Luigi, Yin, Lixue , Villari, B, Pellikka, Patricia A, Picano, Eugenio, Zagatina, A , Ciampi, Quirino , Wierzbowska‐Drabik, Karina , Kasprzak, Jarosław D. , Ciampi, Quirino , Cortigiani, Lauro , Zagatina, Angela , Padang, Ratnasari , Villarraga, Hector R , Ryabova, Tamara , Rodriguez-Zanella, Hugo , Gaibazzi, Nicola , Pepi, Mauro , Wierzbowska-Drabik, Karina , Kasprzak, Jaroslaw D , Wang, Yi , Kane, Garvan C. , Villarraga, Hector R. , Kalinina, Elena , Lowenstein, Jorge , Arbucci, Rosina , Haber, Diego M. Lowenstein, Čelutkienė, Jelena , Boshchenko, A , Rodríguez‐Zanella, Hugo , Bursi, Francesca , Đorđević-Dikić, Ana, Amor, Miguel , Haberka, Maciej , Safarova, Ayten, Nikolic, Aleksandra, Gaibazzi, Nicola , Kovačević-Preradović, Tamara , Tripepi, Giovanni Luigi , Villari, Bruno, Carerj, Scipione , Pellikka, Patricia A. , Picano, Eugenio

Mayo Clinic

ESC Heart Failure | May 23, 2026 | Volume: 13 | Issue: 4 | Pages: No page available

10.1093/eschf/xvag151 | PMID 42249823 Get It

Abstract Introduction Transthoracic echocardiography (TTE) identifies a hypercontractile phenotype (HP) in chronic coronary syndromes (CCS), characterized by elevated resting left ventricular (LV) elastance (force = systolic blood pressure/end-systolic volume). To evaluate the prognostic significance and functional correlates of HP. Methods In a prospective multicentre study, 10 677 patients with CCS underwent resting TTE to assess LV ejection fraction (EF), stroke volume, and force by quantitative volumetric echocardiography. All patients were followed for the endpoint of all-cause mortality. In a subset of 5834 patients, stress echocardiography (exercise or dobutamine) was performed for LV contractile reserve and heart rate reserve. Results Patients were stratified into Force quintiles (Q1–Q5). Patients with hypercontractile phenotype exhibited lower stroke volume at rest (Q5 = 34.8 ± 12.3 vs Q1–Q4 = 57.4 ± 19.1 mL; P < .01) and higher EF at rest (Q5 = 64.8 ± 6.9% vs Q1–Q4 = 58.1 ± 8.7%, P < .01). During a median follow-up of 24 months (interquartile range = 12–40 months), 509 deaths occurred. The exposure-adjusted death rate was lowest in Q3 (3.53–4.51 mmHg/mL; 1.03 per 100 person/years) and higher in Q1 (≤2.62 mmHg/mL, 2.88), Q2 (2.63–3.52 mmHg/mL, 1.86), Q4 (4.52–6.11 mmHg/mL, 1.56), and Q5 (HP, >6.11 mmHg/mL; 1.88; P < .0001 vs Q1 and Q3). Multivariable analysis identified HP (Q5; HR 1.531 vs Q3, 95% CI 1.116–2.099; P = .006) and EF (HR 0.963, 95% CI 0.953–0.972; P < .0001) as independent predictors of death. During exercise or dobutamine stress, HP showed reduced LV contractile reserve (ΔEF: Q5 = 4.3 ± 9.4% vs Q1–Q4 = 7.0 ± 9.3%; P < .001) and blunted heart rate reserve (Q5 = 1.77 ± 0.33 vs Q1–Q4 = 1.85 ± 0.39; P < .01). All patients with force-based LV contractile reserve >4.1 (present in 185, 3.2% of the population) survived. Conclusion Patients with CCS with HP assessed by resting TTE demonstrate higher mortality and multilayered functional impairment, including reduced LV contractile and chronotropic reserves. Hypercontractile phenotype improved the prediction of mortality by EF. A ‘stronger’ heart is, in fact, functionally and prognostically weaker.
A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection
Concepcion, Beatrice P. , Bestard, Oriol, Samaniego, Milagros , Prashar, Rohini , Ansari, M. Javeed , Comai, Giorgia , Gessaroli, Elisa , Rostaing, Lionel, Alberici, Federico , Mannon, Roslyn B. , Augustine, Joshua J. , Wee, Alvin , Poggio, Emilio, DiCocco, Pierpaolo , Shawar, Saed , Maluf, Daniel, Rothstein, David M. , Cherukuri, Aravind, Connolly, Patricia, Rose, Angela, Doshi, Nehal, Gallon, Lorenzo , Donovan, Michael , Bestard, Oriol , Bestard, Oriol , Samaniego-Picota, Milagros , Rostaing, Lionel , Augustine, Joshua , Poggio, Emilio , Leca, Nicolae , Shawar, Saed , Bhati, Chandra , Rothstein, David M , Cherukuri, Aravind , Chang, Anthony , Salem, Fadi E , Kattan, Michael W , Schold, Jesse D , Connolly, Patricia , Doshi, Nehal , Gallon, Lorenzo , Mannon, Roslyn B , Ansari, Mohammed Javeed , Comai, Giorgia , Poggio, Emilio D. , Maluf, Daniel G. , Kattan, Michael W. , Donovan, Michael Joseph

Mayo Clinic

Kidney360 | May 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.34067/kid.0000001208 | PMID 42133442 Get It

Background: Although donor and recipient characteristics are used to estimate graft failure risk, they remain limited in predicting early acute rejection. We developed and validated a next-generation sequencing (NGS) assay targeting the pre-transplant immunologic profile to predict early acute rejection following kidney transplantation. Methods: This prospective, international study enrolled 321 kidney transplant participants across 13 sites, forming discovery and validation cohorts. Peripheral blood was collected prior to transplant and at 1, 3, 6, 12, and 24 months post-transplant, with protocol biopsies performed at 3 and 12 months, as well as any indication biopsies. Biopsies were assessed by a blinded central pathologist according to the 2019 Banff criteria. The pre-transplant risk assessment (PTRA™) test to evaluate RNA expression of a 29-gene signature algorithm designed to predict early acute rejection risk was clinically validated utilizing 122 deceased donor kidney transplant recipients. Results: PTRA classified 31 of 122 participants (25%) as high-risk and 91 (75%) as low-risk. There were 9 early acute rejection events in the first 60 days post-transplant: 6/31 (19%) in the high-risk group and 3/91 (3%) in the low-risk group. PTRA discrimination for early acute rejection at 60 days post-transplant yielded an AUC of 0.78 (95% confidence interval [CI]: 64.4 to 91.5), p<0.001. A cut-off of ≤45 was defined as low-risk and >45 as high-risk for early acute rejection within 60 days post-transplant. Sensitivity 0.67 (95% CI: 0.36 to 0.97), specificity 0.78 (95% CI: 0.70 to 0.86), positive predictive value 0.19 (95% CI: 0.05 to 0.33), and negative predictive value 0.97 (95% CI: 0.93 to 1.00). The odds ratio comparing patients identified as high- vs low-risk by PTRA was 7.04 (95% CI: 1.64 to 30.2), p=0.009. Conclusions: This study validates the ability of PTRA to stratify kidney transplant recipients as high- or low-risk for early acute rejection using a pre-transplant transcriptomic profile, with implications for graft health and personalized treatment management.
Benefits of Electronic Symptom Monitoring During Cancer Treatment by Age, Sex, Race, and Education (Alliance AFT-39)
Deal, Allison M. , Sampathkumar, Yashasvini , Ginos, Brenda, Schrag, Deborah , Jansen, Jennifer , Stover, Angela M. , Carr, Philip M., Spears, Patricia A. , Jönsson, Mattias , Thanarajasingam, Gita , Rogak, Lauren , Cella, D, Given, Barbara, Zylla, Dylan M. , Weiss, Anna, Wolf, Anna P., Basch, Ethan , Blinder, V. S., Ginos, Brenda F, Mazza, Gina L , Schrag, Deborah , Jansen, Jennifer , Stover, Angela M , Spears, Patricia A , Jonsson, Mattias , Bennett, Antonia V , Thanarajasingam, Gita , Rogak, Lauren J , Reeve, Bryce B. , Snyder, Claire , Cella, David , Given, Barbara , Zylla, Dylan , Dueck, A. C. , Basch, Ethan , Blinder, Victoria S , Carr, Philip, Geoghegan, Cindy , Given, Barbara , Blinder, Victoria

Mayo Clinic

JCO Oncology Practice | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-26-00015 | PMID 42119041 Get It

PURPOSE Remote symptom monitoring using patient-reported outcomes (PROs) has been shown to improve symptom control and physical function among patients with advanced cancer. However, it is unclear whether these benefits are similar across demographic groups. This exploratory analysis of the PRO-TECT trial examined whether the effects of electronic symptom monitoring varied by race, age, sex, and educational attainment. METHODS PRO-TECT was a cluster randomized trial conducted across 52 US community oncology practices comparing weekly electronic symptom monitoring with usual care (UC). Adult patients with metastatic solid tumors receiving systemic therapy were enrolled (N = 1,191). Participants in the PRO arm completed weekly symptom surveys including the PRO-CTCAE, triggering alerts to the care team for severe or worsening symptoms. Patients chose whether to complete weekly PROs online or via telephone-based interactive voice response not requiring Internet access. Outcomes were measured using the European Organisation for Research and Treatment of Cancer QLQ-C30 symptom control and physical function scales. Subgroup analyses were performed by race (Black v White), age (<65 v ≥65 years), sex (male v female), and educational attainment (≤high school v >high school). RESULTS From baseline to 3 months, PRO participants showed greater improvements in symptom control (+2.37 v −0.20, P = .002) and physical function (+1.54 v −0.93, P = .02) versus UC. Benefits were most pronounced among younger, female, Black, and less educated participants. Black participants in the PRO arm were more likely to report that symptom reporting made them feel more in control of their care compared with White participants. CONCLUSION Electronic symptom monitoring improved quality-of-life outcomes overall, including among groups who have historically experienced higher symptom burden or barriers to communication. Remote PRO systems may represent an equitable strategy to enhance cancer care delivery.
The Role of Emergency Medical Services in Addressing Opioid Use Disorder—A Position Statement and Resource Document of NAEMSP
Mercer, Mary P. , Murrell, Angela, Simpson, Nicholas, Knotts, Mary, Crowe, Remle, Weston, Benjamin W. , Cabañas, José G. , Cage, Todd M , Hickerson, Meredith, Glenn, Melody J , Mercer, Mary P , Murrell, Angela , Crowe, Remle , Cabañas, Jose G , Cage, Todd M , Hickerson, Meredith , Joiner, Anjni P , Simpson, Nicholas, Crowe, Remle P.

Mayo Clinic

Prehospital Emergency Care | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.1080/10903127.2026.2668009 | PMID 42114053 Get It

Encounter tool for Shared Decision Making about Adjuvant Treatment of Lung Cancer: Randomized Clinical Trial
Bandi, Satya Sai Sri, Branda¹, Megan E, Chavez¹, Maria Mateo, Bagewadi¹, Shubhangi, Norman², Aurora S., Montori, Victor, Hargraves¹, Iris G., Boehmer¹, Kasey, Stephen¹, Angela, Sagen¹, Christi, Montori¹, Victor M., Brito¹, Juan P, Leventakos, Konstantinos, Branda, Megan E. , Norman, Aurora S, Hargraves, Iris G., Boehmer, Kasey, Stephen, Angela, Sagen, Christi, Montori, Victor , Gionfriddo, Michael R. , HARGRAVES, IRIS G., Boehmer, Kasey R. , Sagen, Christi, Montori, Víctor M.

Mayo Clinic

No container title available | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8843093/v1 | PMID 42183367 Get It

Abstract Background Lung cancer is the leading cause of cancer-related death, and the most common cancer diagnosed globally. Approximately 85% of lung cancer cases are non-small cell lung cancer (NSCLC). After initial surgical treatment, adjuvant therapy with conventional or targeted chemotherapy can help optimize survival. These treatments, however, must be tailored to each patients’ problematic situation, including cancer characteristics and goals of care. Shared decision making (SDM) is a method of care by which patients and clinicians work together to form plans of care that advance the patient’s problematic human situation. This method often requires evaluating alternative options, “trying them on” for fit given their practical demands and favorable and unfavorable effects. Tools used within the encounter can facilitate and support SDM conversations, yet none exist for considering care post-surgical treatment of NSCLC. Therefore, we aimed to evaluate the effectiveness of a novel encounter tool for SDM, NSCLC Choice, compared to usual care at improving SDM and reducing decisional conflict for patients with resected early-stage NSCLC considering adjuvant treatment. Methods We will conduct a parallel, patient-level randomized trial comparing NSCLC Choice with usual care. Patients will be eligible if they are adults with stage >1B NSCLC eligible for postsurgical adjuvant chemotherapy. Allocation will be central and post-consent. Patients will be blinded to our trial hypothesis, instead of being invited to evaluate an educational intervention. Our primary outcome is SDM quality, which we will assess using participant reported measures (patient SDM-Q-9) obtained immediately post-encounter and an observer measure estimated from video recording of trial encounters in both arms (OPTION12). With resources to conduct a 100-patient trial, we will have >80% power to detect a 12-point medium difference between arms in patient-reported SDM-Q-9. We will also assess the secondary outcomes of knowledge about the disease and the features of treatment options using an ad hoc questionnaire, decisional conflict using the Decisional Conflict Scale, and patient and clinician satisfaction using the metrics used in prior SDM intervention trials. We will also determine encounter length using video recordings. Discussion In testing NSCLC Choice, we seek to determine the extent to which this intervention can improve care for patients with NSCLC considering adjuvant therapy after surgery. In addition, we expect to determine whether this intervention is satisfactory to participants and feasible in practice. If successful, this study will result in an evidence-based tool for promoting patient-centered conversations around NSCLC and cancer care those fits. Trial Registration: NCT06122064 ClinicalTrials.gov
Predictors of renal response in AL amyloidosis following anti‐plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype
Rees, Matthew J., Yohannan, Binoy, Geyer, Susan M. , Atallah‐Yunes, Suheil Albert , Toumeh, Nadia , Gertz, MA, Dispenzieri, Angela, Leung, Nelson , Hayman, Suzanne, Buadi, Francis, Dingli, David, Warsame, Rahma, Kapoor, Prashant , Kourelis, Taxiarchis, Gonsalves, Wilson, Kumar, Shaji, Gertz, Morie A. , Geyer, Susan , Gertz, Morie A , Cook, Joselle M , Rajkumar, S Vincent , Muchtar, E , Leung, Nelson , Atallah-Yunes, Albert , Rees, Matthew J. , Yohannan, Binoy, Dispenzieri, Angela , Hayman, S., Buadi, Francis K. , Cook, Joselle , Dingli, David , Warsame, Rahma , Binder, Moritz , Kourelis, Taxiarchis , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Kumar, Shaji , Muchtar, Eli

Mayo Clinic

British Journal of Haematology | May 11, 2026 | Volume: 209 | Issue: 1 | Pages: 149-159

10.1111/bjh.70542 | PMID 42108212 Get It

Summary Renal response (RenR) in light‐chain (AL) amyloidosis is associated with a lower risk of end‐stage kidney disease and improved survival. However, substantial variation exists in the time to and depth of RenR. We investigated variables associated with RenR in a retrospective study of newly diagnosed AL amyloidosis patients ( n = 350) assessable for RenR between 2010 and 2022. RenRs were recorded at 6, 12 and 24 months and best response. Deep RenR was defined as a ≥renal very good partial response (RenVGPR, >60% reduction in 24‐h proteinuria or ≤200 mg). Logistic regression and competing risk methods were used to examine variables associated with RenR. The median age was 64 years, and median follow‐up was 5.5 years. On multivariable logistic regression, obtaining ≥HemVGPR within 6 months, kappa isotype, high baseline difference between involved and uninvolved free light chains (dFLC ≥40 mg/dL), renal stage and autologous haematopoietic stem cell transplant (AHSCT) were significantly associated with deep RenR. Cumulative incidence rates for deep RenR, treating death or renal progression as a competing event, demonstrated that early HemR, first‐line AHSCT, lower renal stage and dFLC ≥40 mg/dL significantly increased the likelihood of deep RenR. Specific clonal plasma cell features, namely light‐chain isotype and baseline dFLC levels, independently influence the timing and depth of RenRs in AL amyloidosis following treatment, in addition to renal stage and HemR.
Real‐World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease
Nishimura, Yoshito, Estevez, Maria Santiago, ASAD, HAKEEM , Habermann, T. M., Habermann, Thomas M. , Habermann, Thomas , Nishimura, Yoshito , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | May 9, 2026 | Volume: 101 | Issue: 8 | Pages: 2033-2037

10.1002/ajh.70352 | PMID 42104162 Get It